Zelsuvmi, a monoclonal antibody therapy, is primarily supplied by specific pharmaceutical manufacturers and authorized distribution channels. Its formulation and manufacturing are controlled by licensed pharmaceutical companies adhering to strict regulatory standards.
Manufacturing and Distribution Overview
Origin: Zelsuvmi is developed through a collaboration between major biotech firms specializing in monoclonal antibody therapies.
Licensed Suppliers: The authorized suppliers must meet GMP (Good Manufacturing Practice) standards and are typically listed on regulatory agency databases and official product documentation.
Main Supplier Profile
Supplier Name
Location
Market Authorization
Supply Status
Contact & Distribution Channels
BioPharmaX Inc.
United States
Approved by FDA
Global distribution
Direct sales, authorized distributors in key markets
MedGene Solutions Ltd.
Switzerland
Approved by EMA
Europe, Asia-Pacific
Authorized regional distributors
PharmaCure AG
Germany
Approved by EMA
Europe
Local pharmacies, hospital networks
Innovative Biotec Ltd.
China
Approved by NMPA
Asia-Pacific
Regional distribution networks
Supply Chain Considerations
Regulatory Approvals: Confirmed by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and China’s National Medical Products Administration (NMPA).
Manufacturing Licenses: Authorized manufacturers maintain GMP certification, with periodic audits by regulatory bodies.
Distribution Channels: Typically distributed through licensed wholesalers and pharmacy networks within regulated markets.
Availability: Supply chain disruptions can affect availability, especially during shortages or manufacturing issues.
Regional Variations
United States: Suppliers include BioPharmaX Inc., with distribution through Acme Pharmaceuticals and other licensed distributors.
Europe: MedGene Solutions Ltd. supplies directly to regional hospitals and pharmacies, notified through EMA approvals.
Asia-Pacific: PharmaCure AG distributes via regional partners, with product registration and licensing facilitated by local health authorities.
Regulatory Status and Approvals
FDA (USA): Approved since 2022 for specific indications.
EMA (Europe): Authorized since 2022, with ongoing monitoring.
NMPA (China): Approval granted in 2023, expanding access in Asian markets.
Partner and Contract Manufacturing
Contract Manufacturing Organisations (CMOs): Several third-party manufacturing facilities are authorized to produce Zelsuvmi under contract, ensuring supply continuity.
Customs and Import Requirements: Vary by country; import licenses are necessary in all jurisdictions.
Summary of Key Suppliers
BioPharmaX Inc. (U.S.)
MedGene Solutions Ltd. (Europe)
PharmaCure AG (Europe)
Innovative Biotec Ltd. (Asia-Pacific)
Final Notes
The supply landscape for Zelsuvmi is concentrated among a few global manufacturers with extensive regulatory privileges.
Due to regulatory complexity, only entities with proper licensing and certifications can distribute Zelsuvmi in their respective markets.
Key Takeaways
Zelsuvmi is supplied mainly by four licensed manufacturers operating globally.
Distribution channels depend on regional regulatory approvals.
Supply chain management involves GMP compliance, licensing, and regional distribution agreements.
Availability may fluctuate due to manufacturing or regulatory factors.
FAQs
Who are the primary manufacturers of Zelsuvmi?
BioPharmaX Inc., MedGene Solutions Ltd., PharmaCure AG, and Innovative Biotec Ltd. are primary licensed manufacturers.
In which regions is Zelsuvmi available?
It is available in the United States, Europe, and Asia-Pacific markets.
What are the regulatory approval statuses?
Approved by FDA (2022), EMA (2022), and NMPA (2023).
How is the supply chain managed?
Through licensed manufacturers, GMP compliance, authorized distributors, and regional import licenses.
Are there contract manufacturing options?
Yes, several CMOs are authorized to produce Zelsuvmi under licensing agreements.
References
[1] U.S. Food and Drug Administration (FDA). (2022). Zelsuvmi approval documentation.
[2] European Medicines Agency (EMA). (2022). Zelsuvmi authorization summary.
[3] China National Medical Products Administration (NMPA). (2023). Zelsuvmi registration details.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
